CCAAT/enhancer-binding protein a (C/EBPa) is mutated in 10% of acute myeloid leukemias, resulting in either a truncated protein or an altered leucine zipper (C/EBPaLZ) that prevents DNA binding. C/EBPa induces bcl-2 in cooperation with nuclear factor-jB (NF-jB) p50 to inhibit apoptosis. We now demonstrate that C/EBPa or a C/EBPaLZ oncoprotein binds the bcl-2 P2 promoter in chromatin immunoprecipitation assays and induces the promoter dependent on the integrity of a jB site. C/EBPa expressed as a transgene in B cells binds and activates the bcl-2 promoter, but not in nfkb1À/À mice lacking NF-jB p50. Bcl-2 is central to the intrinsic apoptotic pathway, whereas FLICE inhibitory protein (FLIP) modulates caspase-8, the initiator caspase of the extrinsic pathway. C/EBPa and C/ EBPaLZ also bind the FLIP promoter and induce its expression dependent upon NF-jB p50. Moreover, induction of FLIP by C/ EBPa protects splenocytes from Fas ligand-induced apoptosis, but only if p50 is present. We also demonstrate the direct interaction between bacterially produced C/EBPa and NF-jB p50, mediated by the C/EBPa basic region. These findings indicate that C/EBPa or its oncoproteins activate the bcl-2 and FLIP genes by tethering to their promoters through bound NF-jB p50. Targeting their interaction may favor apoptosis of transformed cells.
Introduction
CCAAT/enhancer-binding protein a (C/EBPa) is the founding member of a family of transcription factors having a C-terminal amphipathic leucine-rich dimerization domain (leucine zipper, LZ), a basic amino acid-rich DNA-binding domain (basic region, BR) and N-terminal transactivation domains. [1] [2] [3] The full-length protein is 42 kDa, and initiation of translation from an internal AUG results in a truncated 30 kDa protein (C/EBPap30) lacking one transactivation domain. Within hematopoiesis, C/EBPa is critical for myeloid differentiation [4] [5] [6] [7] [8] and is mutated in 5-15% of acute myeloid leukemia (AML) patients with normal cytogenetics. [9] [10] [11] [12] [13] The AML-associated mutations can be grouped into two clusters. Changes in the N-terminal region lead to expression of C/EBPap30, which has a dominant-negative effect and altered DNA binding. 11, 14 Mutations in the C-terminal region (C/EBPaLZ) are typically in-frame insertions or deletions, interrupting the a-helical conformation of the LZ domain and preventing dimerization, and thereby also DNA binding, as C/EBPa binds DNA as an obligatory dimer. 10, 11 Interestingly, C/EBPa null mutations have not been described in AML, suggesting that expression of the mutated isoforms is of functional importance for a malignant cell. In addition to mutations in the CEBPA gene, the products of common AMLrelated translocations interfere with C/EBPa expression. AML1-ETO binds and represses the CEBPA promoter, FLT3-ITD signaling reduces CEBPA mRNA expression and bcr-abl inhibits CEBPA translation. [15] [16] [17] Dysregulation of transcription factors in leukemia is common. 18 These altered proteins often contribute to leukemogenesis through blockade of differentiation and stimulation of proliferation. Uniquely, C/EBPa protects hematopoietic cells from apoptosis by inducing bcl-2, potentially in cooperation with the p50 subunit of nuclear factor-kB (NF-kB). 19 The AMLassociated C/EBPa mutants, including C/EBPaLZ variants that cannot bind DNA, retain the ability to induce bcl-2. 19 Dysregulated apoptosis is an important feature of the malignant phenotype in AML, contributing to the high rate of therapy failure. [20] [21] [22] [23] The bax/bcl-2 ratio impacts the prognosis of patients with AML independent of cytogenetics, and the leukemic cells are resistant to Fas-mediated apoptosis. 24 However, the underlying mechanisms that allow many AMLs to resist apoptosis remain uncertain. Here we show that C/EBPa or a C/EBPaLZ oncogenic variant interacts directly with NF-kB p50 to bind and activate the endogenous bcl-2 promoter. Interaction with NF-kB p50 is shown to be essential for the activation of bcl-2 by C/EBPa. In addition, C/EBPa or its C/ EBPaLZ mutant also binds and activates the FLICE inhibitory protein (FLIP) promoter dependent on the presence of NF-kB p50, and the induction of FLIP by C/EBPa reduces apoptosis and cell death induced by Fas ligand (FasL), indicating that C/EBPa and NF-kB p50 cooperate to regulate both the extrinsic and intrinsic apoptosis pathways. We also demonstrate using purified proteins that C/EBPa and NF-kB contact each other directly. The potential for targeting interaction of these proteins as an approach to therapy for AML or other malignancies will be discussed.
Materials and methods

Cells, plasmids and transient transfection
Ba/F3 cells 19 were cultured in RPMI-1640 with 10% heatinactivated fetal bovine serum (HI-FBS) and 1 ng/ml interleukin (IL)-3 (Peprotech, Rocky Hill, NJ, USA). HF-1 cells 25 were maintained in Iscove's modified Dulbecco's medium, 10% HI-FBS and 2.5 ng/ml granulocyte macrophage-colony-stimulating factor (Peprotech). F9 and 293T cells were grown in Dulbecco's modified Eagle's medium with 10% HI-FBS. C/EBPa or the human AML-derived C/EBPaLZ mutant F3901 (DK312) 10 was cloned into the MTCB6 plasmid downstream of the metallothionein (MT) promoter. ScaI linearized plasmid DNAs were electroporated into Ba/F3 cells, and stably expressing cells were selected using 1.2 mg/ml G-418. Expression from the MT promoter was induced by culturing cells with 100 mmol/l zinc chloride, and estradiol was used at 1 mmol/l. Cytomegalovirus (CMV) expression vectors encoding C/EBPa, C/EBPaGZ, 26 NF-kB p50 and NF-kB p65 were described earlier. 19 CMV-C/ EBPabZIP encodes the COOH-terminal amino-acid residues 273-359 of rat C/EBPa. The bcl-2 P2-LUC reporter (containing base pairs À1278/ þ 1) and its À170 bp NF-kB-binding site mutant were described earlier. 27 F9 cells were transfected in 60 mm dish using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Each plate was transfected with 1.5 mg of the reporter plasmid, with 100 ng control CMV vector or CMV-C/EBP plasmids, and 5 ng CMV-b-galactosidase as an internal control. Luciferase and b-galactosidase activities were assayed 48 h after the transfection.
Mice H2K-C/EBPa-Em transgenic (aTG) mice in which the rat C/EBPa is expressed from the H2K promoter upstream of the immunoglobulin heavy-chain enhancer were described earlier. 19 The transgene was detected by PCR of tail DNA using the following primers:
aTG-F: 5 0 -CCATCTCCACAGTTTCACTTCTGC; aTG-R: 5 0 -CCGCGGCTCCGCCTCGTAGAAGTCG. Nfkb1À/À mice 28 or the B6;129PF1 strain-matched controls (Jackson Laboratories, Bar Harbor, ME, USA) were genotyped by PCR using the following primers: nfkb1-common: 5 0 -GCAAACCTGGGAATACTTCATGTGACT AAG; nfkb1-WT: 5 0 -ATAGGCAAGGTCAGAATGCACCAGAAGTCC; nfkb1-KO: 5 0 -AAATGTGTCAGTTTCATAGCCTGAAGAACG. Bone marrow cells were extracted from the hindlimbs. Singlecell suspensions of splenocytes were obtained from wild-type (WT), WT;aTG, nfkb1À/À and nfkb1À/À;aTG mice using a cell strainer, and the cells were cultured in RPMI-1640 with 10% HI-FBS and 50 nmol/l b-mercaptoethanol. Red cells were removed using an Accu-Prep gradient (Accurate Chemicals, Westbury, NY, USA). For Fas-mediated apoptosis, cells were cultured in RPMI-1640, 10% HI-FBS and 50 mg/ml lipopolysaccharide (List Biological Laboratories, Campbell, CA, USA) for 30 h. 29 The splenocytes were then exposed to soluble FasL (Alexis Biochemicals, San Diego, CA, USA) for 16 h. Cell viability and apoptosis were assessed by staining with allophycocyaninconjugated annexin V and propidium iodide followed by analysis using a fluorescence-activated cell sorter.
Western blotting, co-immunoprecipitation and gel shift assay
Western blot and co-immunoprecipitation (co-ip) were performed as described earlier. 19 For co-ip, 293T cells in 100 mm dishes were transfected using Lipofectamine 2000. Bacterially produced proteins were coincubated at 4 1C for 1 h in 150 mmol/l NaCl, 20 mmol/l Tris (pH 7.5), 0.5% Triton X-100, 1 mmol/l EDTA and then subjected to immunoprecipitation as described. 19 The following antibodies were used: C/EBPa (14AA), bcl-2 (N19), NF-kB p50 (NLS) and NF-kB p65 (C20), mouse monoclonal anti-b-tubulin (D-10) and mouse monoclonal NF-kB p50 (E10; Santa Cruz Biotechnology, Santa Cruz, CA, USA), mouse anti-C/EBPa (MA1-825; Affinity Bioreagents, Golden, CO, USA) and rabbit anti-C/EBPa COOH terminal. 5 Bands were quantified using NIH ImageJ software. Purified C/ EBPa protein was subjected to gel shift analysis as described. 30 The sequence of the sense strand C/EBPa (NE) oligonucleotide with 4 bp overhang was 5 0 -TCGAGGCCAGGATGGGGCAATA CAACCCG. The kB oligonucleotide with 1 bp overhang was 5 0 -GGGGGAATCCCC.
Chromatin immunoprecipitation
Ten million Ba/F3, HF-1 or mouse whole bone marrow cells were used in each chromatin immunoprecipitation (ChIP) reaction. Cells were incubated with 1% formaldehyde at 37 1C for 10 min, and the reaction was quenched with glycine at a final concentration of 0.125 M. Cells were washed twice with ice-cold phosphate-buffered saline containing 1 mM phenylmethylsulfonyl fluoride and Protease Inhibitor Cocktail (Sigma, St Louis, MO, USA) and resuspended in 1 ml ChIP lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris (pH 8.0), 1 Â protease inhibitors). Lysates were sonicated on ice using a Branson Sonifier 250, and the chromatin was sheared to 500-to 1000-bp fragments. Lysates were centrifuged for 10 min at 16 000 g to remove insoluble cell debris, and ChIP dilution buffer (167 mM NaCl, 16.7 mM Tris (pH 8.0), 1.1% Triton X-100, 0.01% SDS, 1.2 mM EDTA and 1 Â protease inhibitors) was added to a final volume of 4 ml. Lysates were precleared with 65 ml blocked protein-A/G sepharose beads (Upstate Biotechnologies, Lake Placid, NY, USA) for 1 h at 4 1C. They were briefly centrifuged, and input was obtained before incubating the resulting supernatant with the antisera against C/EBPa, C/EBPb, NF-kB p50, NF-kB p65 or rabbit IgG (Santa Cruz Biotechnology) overnight at 4 1C with rocking. Sixty microliters of blocked protein-A/G sepharose beads were added, followed by incubation at 4 1C for 2 h with gentle agitation. The beads were precipitated by centrifugation, and the bead-bound complexes were washed for 5 min in each of the following buffers: low-salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris (pH 8.0) and 150 mM NaCl), high-salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris (pH 8.0) and 500 mM NaCl), LiCl wash buffer (0.25 M LiCl, 1% IGEPAL CA-630, 1% sodium deoxycholate, 1 mM EDTA, 10 mM Tris (pH 8.0)) and two washes in TE (10 mM Tris (pH 8.0) and 1 mM EDTA). DNAprotein complexes were eluted from beads using 200 ml of 1% SDS and 0.1 M NaHCO 3 at room temperature. Cross-links were reversed by adding 10 ml of 4M NaCl to the eluates and incubation at 65 1C overnight. Each sample was treated with RNAse and proteinase K, and DNA was isolated with UltraClean DNA Purification Kit (Mo Bio Laboratories, Carlsbad, CA, USA). Precipitation of promoters of interest was detected by PCR, and the PCR products were resolved on agarose gels and visualized using ethidium bromide. The following primers were used: P1-F: 5 0 -CTGGAGGTCTGAAGCGGTC; P1-R: 5 0 -AGTCCAG CATTTGCAGAAGTC; P2-F: 5 0 -CATTGGTACCTGCAGCTTC; P2-R: 5 0 -CTGTGACA GCTTATAATGTATG; FLIP-F: 5 0 -CGCCCGGTAGTGTCTCTATT; FLIP-R: 5 0 -CTCGTC CAGTCTCCATCCAT; NE-F: 5 0 -ATGGATGATGCTGAAATGGAG; NE-R: 5 0 -CTCACC ACCCAGGAACAATG.
Reverse transcriptase and quantitative PCR
Total cellular RNAs were extracted using the RNeasy kit (Qiagen Inc., Valencia, CA, USA) according to the manufacturer's protocol, and first-strand cDNA was synthesized from 1 mg of RNA using the ImProm II Reverse Transcriptase System (Promega, Madison, WI, USA). Quantitative real-time PCR was performed using the iCycler iQ Real Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA, USA) with a total reaction volume of 25 ml per reaction using the iQ SYBR Green Supermix (Bio-Rad). Each sample was assayed in triplicate, and mouse ribosomal protein S16 (mS16) transcript levels were used to normalize between samples. Standard curves were constructed for each assay to ensure high amplification efficiencies and comparability across all assays. The comparative C t method was employed for quantification of the transcript expression levels. Triplicate C t values were generated for all assays, and 2 ÀDDCt values were then calculated. 
Bacterially expressed proteins
The full-length rat C/EBPa DNA was cloned as an NdeI/XhoI fragment into the pET28a( þ ) vector (EMD Biosciences, Gibbstown, NJ, USA), resulting in an N-terminal linker containing six histidine residues. The NF-kB p50 Rel homology domain (RHD) corresponding to residues 39-366 was cloned as a XmaI/XhoI fragment into a modified version of the pET22b( þ ) vector (EMD Biosciences). The resulting construct included an N-terminal eight-histidine residue repeat. Codon-adjusted Escherichia coli bacteriae Rosetta2-DE(3) (EMD Biosciences) were transformed, grown and induced with isopropyl-b-D-1-thiogalactopyranoside (IPTG) at a final concentration of 100 mM. For C/EBPa purification, the bacteriae were lysed (50 mM Tris-Cl, 200 mM NaCl (pH 7.3), 5 mM b-mercaptoethanol, 2-3 mg lysozyme, 1 mM Pefabloc SC (Sigma) and Protease Inhibitor Cocktail (Sigma)), sonicated and centrifuged at 34 000 g for 1 h. The supernatant was loaded on equilibrated Hi-Trap Ni-NTA columns (GE Healthcare, Piscataway, NJ, USA). After washing with buffer A (50 mM Tris-Cl, 200 mM NaCl (pH 7.3) and 5 mM b-mercaptoethanol), the proteins were eluted with 50, 100, 200 and 500 mM immidazole using a step-gradient method. Fractions containing C/EBPa were pooled, unfolded for 1 h in 37 1C using urea (final concentration, 8 M) and dithiothreitol (final concentration, 1 mM), centrifuged at 15 000 g for 30 min and stored at À80 1C. The optimal refolding conditions were determined using the QuickFold Protein Refolding Kit (Athena Environmental Sciences, Baltimore, MD, USA). After thawing, the purified C/EBPa was refolded using a buffer containing 50 mM Tris-Cl, 9.6 mM NaCl, 0.4 mM KCl, 1 mM EDTA, 0.5% Triton X-100 and 1 mM dithiothreitol (pH 8.5). Bacteriae expressing the NF-kB p50 RHD were lysed (25 mM Tris-Cl, 50 mM NaCl, 5 mM b-mercaptoethanol, 2.5 mg lysozyme, 1 mM PEFA (pH 7.5) and Protease Inhibitor Cocktail (Sigma)), sonicated on ice and centrifuged at 34 000 g for 1 h. The supernatant was loaded on equilibrated Hi-Trap Ni-NTA columns and subsequently washed in buffer containing 25 mM Tris-Cl, 50 mM NaCl and 5 mM bmercaptoethanol (pH 7.5). RHD was eluted with an immidazole gradient as described above, and fractions containing RHD were pooled, dialyzed against 25 mM Tris-Cl (pH 7.5) and 50 mM NaCl, and stored at À80 1C.
Statistics
Statistical comparisons were performed using the Student's t-test.
Results
C/EBPa binds the endogenous bcl-2 promoter
We employed ChIP to demonstrate binding of C/EBPa to the endogenous bcl-2 promoter. HF-1 is a myeloid cell line expressing C/EBPa. Unstimulated cell lysates were subjected to immunoprecipitation with antisera against C/EBPa, C/EBPb, NF-kB p50, NF-kB p65 or IgG control. The precipitated DNA was purified, and the amplification with primers directed at the bcl-2 P2 promoter demonstrates binding of each of these endogenous proteins to the bcl-2 P2 promoter ( Figure 1a ). Similar findings were obtained in two additional independent experiments (not shown).
To investigate the binding of a C/EBPaLZ leukemic isoform, we generated Ba/F3 cell lines that express WT C/EBPa or the AML patient-derived LZ mutant F3901 under the control of the inducible MT promoter (MT-C/EBPa and MT-F3901, respectively). These cell lines express the C/EBPa isoform at similar levels, and C/EBPa is not expressed in parental Ba/F3 (Figure 1b ). Following culture with zinc chloride for 16 h to induce the MT promoter, cells were subjected to ChIP analysis using antiserum specific for C/EBPa. Both C/EBPa isoforms interacted with the endogenous bcl-2 promoter, and F3901 did so despite its inability to bind DNA directly ( Figure 1c ). No interaction was seen when parental Ba/F3 cells exposed to zinc chloride were analyzed similarly. Neutrophil elastase (NE) is a marker of early granulocytic myeloid differentiation. Remarkably, WT C/EBPa, but not F3901, binds the NE promoter, indicating that LZ oncoproteins expressed in AML bind a specific subset of genes, thereby retaining the antiapoptotic effect of C/EBPa but not its ability to induce differentiation.
C/EBPa and C/EBPa oncoproteins preferentially bind and activate the P2 bcl-2 promoter
The bcl-2 gene is expressed from two promoters, P1 and P2 (Figure 2a ), P1 being more active. Ba/F3-aER cells express a C/ EBPa-estrogen receptor (ER) fusion protein that is inactive in the absence of estradiol. Withdrawal of Ba/F3 or Ba/F3-aER cells from IL-3 leads to a rapid onset of apoptosis; however, this effect is delayed by the activation of C/EBPa-ER, dependent upon induction of bcl-2 expression. 19 Bcl-2 protein expression was evident by 16 h in this earlier study, but RNA expression was not examined. Total cellular RNAs prepared from Ba/F3-aER cells withdrawn from IL-3 in the absence or presence of estradiol were evaluated for bcl-2 mRNA expression by northern blotting (Figure 2b) . Although expressed at low levels, P2 mRNA was induced within 4 h, whereas transcription from the P1 promoter remained constant. To confirm the results of the northern blot, we designed sets of PCR primers corresponding to the P1 or P2 promoters. Ba/F3 MT-C/EBPa or MT-F3901 cells were cultured with zinc chloride, and total cellular RNAs were prepared 16 h after withdrawal from IL-3. First-strand cDNA was analyzed by quantitative PCR. Each sample was assayed in triplicate in each experiment, and mS16 transcript levels were used as an internal control to normalize between samples. Compared with parental Ba/F3 cells, in four different RNA preparations, C/EBPa or F3901 induced P2 transcripts 8.2-or 5.4-fold on average, whereas P1 transcript levels increased only 1.5-or 2.1-fold ( Figure 2c ).
In addition, Ba/F3 MT-F3901 or Ba/F3-C/EBPa cells were induced with zinc chloride for 16 h and subjected to ChIP analysis. In concordance with the RNA analyses, PCR amplification demonstrates binding of F3901 or C/EBPa and NF-kB p50 to the endogenous P2 but not the P1 promoter ( Figure 2d ). Together, these findings indicate that C/EBPa and its leukemiaassociated LZ mutant bind and induce transcription from the endogenous P2 promoter of the bcl-2 gene.
NF-kB p50 is necessary for C/EBPa to bind and activate the bcl-2 promoter
We have shown earlier that C/EBPa and its leukemia-related isoforms synergize with NF-kB p50 to activate the bcl-2 promoter. We now set out to test the hypothesis that absence of p50 would diminish bcl-2 induction by C/EBPa. Splenocytes from H2K-C/EBPa-Em transgenic (aTG) mice are resistant to radiation-induced apoptosis and have increased bcl-2 compared with control littermates when subjected to apoptotic stress. 19 Nfkb1À/À mice and strain-matched WT controls were bred with aTG mice to generate nfkb1À/À;aTG and matched WT;aTG mice. Single-cell suspensions of splenocytes from nfkb1À/À, nfkb1À/À;aTG, WT and WT;aTG mice were exposed to 200 cGy. Total cell lysates obtained 7 and 24 h later were analyzed by western blotting for bcl-2 ( Figure 3a ). As seen earlier, 19 bcl-2 levels were increased 1.5-fold by C/EBPa in WT NF-kB p50 cells (compare lanes 9 and 12). In contrast, the C/EBPa transgene failed to induce bcl-2 in the nfkb1À/À splenocytes 24 h after radiation (compare lanes 3 and 6). Thus, NF-kB p50 is required for the induction of bcl-2 by C/EBPa. We next evaluated the importance of NF-kB p50 for the binding of C/EBPa to the bcl-2 promoter. Bone marrow cells were employed in this experiment as their use offers two advantages over splenocytes. First, they allow evaluation of binding of C/EBPa at physiologic levels and second, they provide a cellular context where C/EBPa is expected to occupy additional genetic targets associated with myeloid differentiation. Total bone marrow cells were subjected to ChIP analysis (Figure 3b ). In the absence of NF-kB p50, C/EBPa only minimally bound the endogenous bcl-2 promoter compared with the strong interaction evident in WT bone marrow cells. On the other hand, NF-kB p50 was not necessary for the binding of C/EBPa to the myeloid NE promoter. In addition, we assessed bcl-2 mRNA expression in WT versus nfkb1À/À marrow mononuclear cells and observed a significant fourfold reduction in bcl-2 RNA expression in the absence of NF-kB p50, whereas NE mRNA levels were not significantly altered (Figure 3c ). Together, these findings lend further support to the conclusion that a subset of C/EBPa genetic targets exist in which binding to the promoter and activation of transcription depend on cooperation with NF-kB p50.
C/EBPa and C/EBPaLZ mutants synergize with NF-kB p50 to transactivate the bcl-2 promoter in the F9 cell line, which has only a low level of endogenous NF-kB proteins. 19 The P2 promoter contains a kB-binding site at À170. 27 F9 cells were co-transfected with P2-LUC or P2-LUCmkB, harboring point mutations in the À170 kB site, and with CMV, CMV-C/EBPa or CMV-C/EBPaF3901. Fold activation was determined relative to the empty CMV vector, and an activation ratio for P2-LUC versus P2-LUCmkB was also calculated for each isoform (Figure 3d ). Mutating the kB site significantly reduced the activation by C/EBPa or its F3901 variant. These findings indicate that activation of the bcl-2 P2 promoter by C/EBPa depends in part on the integrity of the kB site at À170 and supports the idea that C/EBPa or its non-DNA-binding F3901 variant tethers to NF-kB p50 bound to this kB site to activate transcription from the bcl-2 P2 promoter. A residual fivefold activation of P2-LUCmkB by C/EBPa or F3901 suggests the presence of an additional functional kB site in the 1.3 kb P2 promoter.
C/EBPa binds the FLIP promoter and induces FLIP transcription through NF-kB p50
A microarray screen using mRNA from Ba/F3 F3901-ER cells identified FLIP as a potential C/EBPa or F3901 genetic target.
FLIP modulates death receptor activation of caspase-8, the initiator caspase of the extrinsic apoptotic pathway. To validate this finding, parental Ba/F3 cells and MT-C/EBPa or MT-F3901 subclones were induced with zinc chloride for 16 h followed by IL-3 withdrawal for an additional 16 h in the presence of zinc. Total cellular RNAs were extracted, and FLIP expression was analyzed by quantitative reverse transcriptase PCR. Expression was normalized to mS16, encoding a large ribosomal subunit. Compared with parental cells, FLIP was induced 6.5-fold by C/EBPa and 10.5-fold by C/EBPaF3901 (Figure 4a ), on average from three independent RNA preparations. ChIP analysis using similar cells shows binding of C/EBPa or F3901 to the endogenous FLIP promoter, with no interaction evident in parental cells (Figure 4b ). Similar ChIP data were obtained in an independent second experiment with Ba/F3 cell lines (not shown). To determine whether the absence of NF-kB p50 reduces the ability of C/EBPa to induce FLIP expression, we carried out ChIP using WT;aTG and nfkb1À/À;aTG splenocytes. Splenocytes were employed as lymphoid cells are expected to express increased FLIP compared with myeloid cells. Interaction of the C/EBPa transgene with the FLIP promoter was reduced eightfold in the absence of NF-kB p50 (Figure 4c ), whereas no interaction was evident in WT marrow cells (not shown). To determine whether the induction of FLIP by C/EBPa protects cells from death through the extrinsic apoptotic pathway, splenocytes from WT, WT;aTG, nfkb1À/À and nfkb1À/À;aTG mice were exposed to lipopolysaccharide followed by FasL (Figure 4d ). Lipopolysaccharide induces Fas expression, allow- (a) Splenocytes from mice with the indicated genotype were exposed to 200 cGy and cultured for 0, 7 or 24 h. Total cellular protein extracts were obtained and subjected to western blotting for bcl-2 and b-tubulin. The ratio of bcl-2:tubulin in each sample is shown. (b) Total bone marrow cells extracted from nfkb1À/À or wildtype (WT) control mice were subjected to ChIP using C/EBPa (a) or NF-kB p50 (p50) antisera or IgG control and primers specific for the bcl-2 P2 or NE promoters. (c) RNA isolated from total bone marrow cells from the hindlimbs of age-, sex-and strain-matched nfkb1À/À or WT mice was subjected to quantitative RT-PCR analysis of bcl-2 or NE expression, normalized to mS16. Relative mRNA expression between WT and nfkb1À/À mice is shown, with the expression in nfkb1À/À marrow set to 1. Data from four comparisons are shown. (d) F9 cells were transiently cotransfected with 1.5 mg of P2-LUC or its variant harboring clustered point mutations in the À170 kb site (mkB), with 100 ng of CMV, CMV-C/EBPa or CMV-F3901 and 5 ng of CMV-b-galactosidase as an internal control. Activation of the WT and mutant promoters by C/EBPa or F3901 was analyzed 48 h after transfection. Fold activation compared with the empty CMV vector was determined after adjustment for b-galactosidase activity. The mean of four independent experiments is presented. Also shown is the average ratio of P2-LUC:P2-LUCmkB induction by C/EBPa or F3901. The P-values shown compare these induction ratios with the null hypothesis value of 1.0. C/EBPa, CCAAT/enhancer-binding protein a; ChIP, chromatin immunoprecipitation; CMV, cytomegalovirus; NE, neutrophil elastase; RT-PCR, reverse transcriptase PCR.
ing the induction of apoptosis in response to FasL. 29 These results demonstrate that the expression of exogenous C/EBPa in lymphoid cells significantly protects splenocytes from FasLinduced apoptosis and that protection from Fas-mediated apoptosis by C/EBPa requires the presence of NF-kB p50.
C/EBPa and NF-kB p50 interact directly
Exogenous or endogenous C/EBPa or C/EBPa oncoproteins present in mammalian cell extracts interact with endogenous NF-kB p50. 19 To exclude bridging by an additional protein and to further validate drug-targetting efforts by demonstrating that this interaction is direct, we expressed histidine-tagged fulllength C/EBPa and the NF-kB p50 RHD in bacteria. The purified proteins were eluted from the Hi-Trap Ni-NTA columns, and fractions containing maximal C/EBPa or NF-kB p50 RHD, as judged by SDS-polyacrylamide gel electrophoresis, were pooled (Figure 5a ). Purified p50 RHD was soluble and bound a cognate kB site in gel shift analysis (data not shown). In contrast, recombinant C/EBPa formed insoluble inclusion bodies due to misfolding. The aggregated protein was solubilized by denaturation in 8 M urea with 1 mM dithiothreitol. To determine the conditions required for the recovery of a soluble active protein, we screened a commercially available panel of buffer/detergent mixtures for their ability to allow the denatured C/EBPa to refold to an active form, as judged by its ability to bind its cognate DNA sequence (Figure 5b) . The buffer containing 50 mM Tris-Cl, 9.6 mM NaCl, 0.4 mM KCl, 1 mM EDTA, 0.5% Triton X-100 and 1 mM dithiothreitol (pH 8.5) (lane 13) was chosen for subsequent experiments. It is worth noting that the presence of 0.5% Triton X-100 was the only feature common to all the buffers that yielded active proteins.
Purified refolded C/EBPa and NF-kB p50 RHD were mixed and subjected to co-ip using either NF-kB p50 or C/EBPa antisera (Figure 5c, left panels) . This assay reproducibly demonstrated interaction between these bacterially generated proteins. When the co-ip procedure was performed using purified C/EBPa alone with NF-kB p50 antisera or purified RHD alone with C/EBPa antisera, no nonspecific interaction of these proteins with the agarose beads was evident (Figure 5c , right panels). The addition of oligonucleotides containing the C/EBPa(NE) site, a kB site, or both oligonucleotides did not interfere with this interaction (Figure 5d ). These data demonstrate that C/EBPa and NF-kB p50 directly interact in the absence or in presence of their cognate DNAs.
The BR of C/EBPa is sufficient for the interaction with NF-kB p50
The point mutation R303G in the BR of C/EBPa prevents its interaction with NF-kB p50. 19 However, it is not clear if other domains of C/EBPa are required for this interaction. To demonstrate that the BR is sufficient for this interaction, we coexpressed the C/EBPa bZIP domain with NF-kB p50 or NF-kB p65 in 293T cells. The bZIP domain includes C-terminal residues 273-359 that contain only the BR and adjacent LZ. Cell lysates were immunoprecipitated with rabbit NF-kB p50 or NF-kB p65 antisera followed by western blot analysis using rabbit antisera specific for the C terminus of C/EBPa. The bZIP domain of C/EBPa was sufficient for interaction with either NF-kB p50 or p65 (Figure 6a ). A similar pattern was obtained when this experiment was repeated using extracts from 293T cells transfected with C/EBPa (bZIP) alone (data not shown), reflecting the interaction with endogenous NF-kB p50 and p65.
To further define the essential domain required for the C/ EBPa-NF-kB p50 interaction, we used C/EBPaGZ, an isoform in which the majority of the C/EBPa LZ is replaced by the GCN4 LZ, starting at residue 315. 26 293T cells were co-transfected with C/EBPa or C/EBPa-GZ and NF-kB p50 or p65, and lysates obtained 2 days later were subjected to co-ip ( Figure 6b , left and right panels). Replacement of the C/EBPa LZ with that of the yeast transcriptional activator GCN4 did not prevent interaction with NF-kB p50 or NF-kB p65, although affinity for p50 was diminished. When the co-ip procedure was performed after transfection with NF-kB p50 or p65 alone, no nonspecific interactions with the agarose beads were evident (Figure 6b , central panel). Together, these data indicate that 42 amino acids (residues 273-315) that encompass the C/EBPa BR and the first a-helix of its LZ are important for its interaction with NF-kB family members.
Discussion
The key conclusions of this study are that C/EBPa binds and activates the endogenous bcl-2 or FLIP promoters through a direct interaction of the C/EBPa BR with NF-kB p50. A C/ EBPaLZ myeloid oncoprotein that cannot interact with DNA also binds and activates the endogenous bcl-2 and FLIP promoters. These findings have important implications in the role of C/EBPa and other C/EBPs in malignant transformation and in the potential utility of targeting the C/EBP-NF-kB interaction to favor apoptosis of malignant cells.
Earlier, we found that C/EBPa inhibits apoptosis of Ba/F3 cells upon IL-3 withdrawal and induces endogenous bcl-2 protein in Ba/F3 cells or murine splenocytes; in addition, mutation of the C/EBPa BR prevented transactivation of the bcl-2 P2 promoter in cooperation with NF-kB p50 and obviated the interaction of C/EBPa with NF-kB p50 but not p65 in co-ip experiments using extracts from the transfected 293T cells. However, several issues were left unsettled. 19 First, the bcl-2 gene has two promoters, both of which have kB sites, and it was unclear whether one, the other or both were the key targets of the C/EBPa-NF-kB p50 complex. We now demonstrate that C/EBPa or the F3901 C/EBPaLZ oncoprotein specifically induces transcription from the bcl-2 P2 promoter and that these activities are greatly diminished upon mutation of the À170 bp kB site. Second, although C/EBPa induces bcl-2 RNA expression and activates the bcl-2 P2-LUC reporter, it was uncertain whether induction of bcl-2 was through a direct interaction with the endogenous gene. We now demonstrate using ChIP that C/EBPa, F3901 and NF-kB p50 each localizes to the endogenous bcl-2 P2 promoter. Third, although we had correlated loss of C/EBPa interaction with NF-kB p50 and inability to induce bcl-2, we had not proven that the interaction with NF-kB p50 is actually required. Now, we find that C/EBPa does not induce endogenous bcl-2 expression or bind the endogenous bcl-2 P2 promoter in cells derived from nfkb1À/À mice lacking NF-kB p50. Fourth, Activities of the renatured proteins were assessed by their ability to bind a consensus C/EBPa DNA sequence from the NE promoter in a gel shift assay. The lane numbers correspond to those of each buffer (QuickFold Protein Refolding Kit). A complete list of the buffers in the protein refolding kit is available at http://www.athenaes.com/ (c) Purified C/EBPa and NF-kB p50 RHD were coincubated, subjected to IP with C/EBPa or p50 antisera, as indicated, followed by western blot (WB) analysis with the reciprocal antibody (left panels). Purified C/EBPa alone was subjected to IP with p50 antisera, and purified RHD alone was subjected to IP with C/EBPa antisera as additional controls (right panels). (d) Co-immunoprecipitation was assessed after coincubation of purified C/EBPa and NF-kB p50 with double-stranded oligonucleotides containing consensus DNA-binding sites for C/EBPa or p50 (kB), or with both oligonucleotides. C/EBPa, CCAAT/enhancer-binding protein a; IP, immunoprecipitation; NE, neutrophil elastase; RHD, Rel homology domain.
C/EBPa oncoproteins induce bcl-2 and FLIP I Paz-Priel et al although C/EBPa and NF-kB interact when expressed in 293T cells, we had not eliminated the possibility of a bridging protein. Now we demonstrate the direct interaction using purified proteins expressed in bacteria. Fifth, although we had implicated the C/EBPa BR as being required for interaction with NF-kB p50 by showing that BR point mutations prevent interaction, we had not assessed whether the BR was sufficient. We now demonstrate that the bZIP domain alone interacts with NF-kB p50. The bZIP domain includes only the BR and LZ. When we replaced the C/EBPa LZ with the homologous region from GCN4, interaction with NF-kB p50 was maintained, although reduced. Together, these data suggest that BR largely accounts for the contact between C/EBPa and NF-kB p50, although further mutagenic studies and perhaps cocrystallization are required to completely map the C/EBPa BR or LZ amino acids that contribute to affinity for NF-kB p50. Interestingly, the bZIP domain also interacted with NF-kB p65, and the substitution of the GCN4 LZ in C/EBPa did not reduce the affinity for p65, suggesting that NF-kB p65 also predominantly contacts C/EBPa through its BR.
Finally, we envision that C/EBPa cooperates with NF-kB p50 to activate additional genes to regulate apoptosis or other pathways and that induction of at least a subset of these requires tethering of C/EBPa to NF-kB p50 bound to DNA, as we surmise it occurs on the bcl-2 P2 promoter. We now provide evidence indicating that the FLIP gene falls into this category: not only C/EBPa but also the F3901 C/EBPaLZ oncoprotein, which cannot bind DNA but retains the ability to bind NF-kB p50, strongly induce FLIP mRNA in Ba/F3 cells; both C/EBPa and F3901 interact with the endogenous FLIP promoter, as does NF-kB p50; and the interaction of C/EBPa with the FLIP promoter in the ChIP assay is markedly reduced in cells from nfkb1À/À mice. In addition, just as we earlier found that C/EBPa inhibits apoptosis through the intrinsic pathway upon cytokine withdrawal, we now find that C/EBPa also reduces apoptosis through the extrinsic pathway induced by Fas-FasL interaction.
The bZIP domains of C/EBPb and C/EBPd are highly similar to the C/EBPa bZIP domain, and their BR segments are virtually identical. In fact, C/EBPb also inhibits apoptosis of Ba/F3 cells withdrawn from IL-3 (I Paz-Priel and AD Friedman, unpublished). As C/EBPb is widely expressed, we suggest that many cell types and their malignant counterparts express bcl-2, FLIP and other genes due to C/EBP-NF-kB cooperation. NF-kB most commonly exists as p65:p50 or p50:p50 dimers in cells. Each of these complexes includes an NF-kB p50 subunit available to interact with the C/EBP BR, and the p65 subunit also interacts with C/EBPa or C/EBPb, though potentially with a reduced affinity. 19, 31, 32 A subset of C/EBP:NF-kB target genes are regulated by binding of both a C/EBP and an NF-kB dimer to separate cis DNA elements in their regulatory regions, whereas an additional subset of genes bind NF-kB, which then potentially attract one or more C/EBP family member to the promoter through protein-protein interactions, expanding the repertoire of C/EBP target genes. It is worth noting that F3901 retains the ability to induce bcl-2 and FLIP but cannot activate the NE gene, whose promoter does not bind NF-kB p50, indicating a mechanism that allows this C/EBPa oncoprotein to inhibit apoptosis without inducing myeloid differentiation. In fact, CEBPA LZ mutation reduces the expression of WT C/EBPa, thereby interfering with normal differentiation.
Besides genes that regulate apoptosis, C/EBP and NF-kB cooperatively bind and activate multiple genes that contribute to inflammation, including those encoding IL-6, IL-8, granulocytecolony-stimulating factor, serum amyloid, intercellular adhesion molecule-1, superoxide dismutase and mediterranean fever promoter. 4 Notably, the C/EBPb bZIP domain alone increases the activity of the IL-6 promoter and does so only if the adjacent NF-kB-binding site is intact. 33 We propose that the direct interaction of C/EBP family members with NF-kB dimers inhibits both the intrinsic and extrinsic apoptosis pathways through the induction of bcl-2, FLIP and other genetic targets and is also important for the induction of inflammation. Although we did not detect an interaction of C/EBPa with the FLIP promoter in normal marrow mononuclear cells, this does not preclude the regulation of FLIP by C/EBPa in a small subset of these cells. In fact, FLIP was detected at high levels in human CD34 þ stem cells, which represent o1% of marrow cells, but not in CD34 À cells, and the immature CD34 þ cells are resistant to Fasmediated killing. 34 Increased expression of bcl-2 family members or FLIP contributes to resistance of leukemias and lymphomas to apoptosis. [20] [21] [22] [23] [24] [35] [36] [37] In addition, elevated FLIP is detected in prostate cancers, and activation of the NF-kB pathway is a common feature of breast cancers, which also often express a truncated C/EBPb isoform. [38] [39] [40] A small molecule that blocks the C/EBP-NF-kB interaction might favor cell death in these and other malignancies and may also reduce inflammation that produces growth and angiogenic factors that themselves contribute to the survival of solid tumors. 41 Figure 6 The C/EBPa basic region mediates its interaction with NF-kB p50 or p65. (a) 293T cells in 100 mm dishes were co-transfected with 2 mg of CMV-C/EBPabZIP and 2 mg of either CMV-NFkB p50 or CMV-NF-kB p65. Two days later, cell extracts were immunoprecipitated with p50 or p65 rabbit antisera (Ab) or rabbit IgG control (Ig) and immunoblotted with rabbit antiserum raised against the C/EBPa COOH-terminal sequence. (b) Extracts from cells transfected with CMV-C/EBPa or CMV-C/EBPaGZ and either CMV-NF-kB p50 or CMV-NF-kB p65 were immunoprecipitated with C/EBPa antiserum or rabbit IgG and immunoblotted with monoclonal p50 or p65 antibodies, as indicated (right and left panels). Extracts from cells transfected with p50 or p65 alone were assayed similarly as additional controls (central panel). C/EBPa, CCAAT/enhancer-binding protein a; CMV, cytomegalovirus.
